Anterior mitral isthmus line using pulsed-field ablation with the pentaspline catheter or radiofrequency ablation: procedural characteristics, safety, and mid-term outcomes

采用脉冲场消融术(使用五角形导管)或射频消融术治疗前二尖瓣峡部线:手术特点、安全性和中期疗效

阅读:2

Abstract

AIMS: Pulsed-field ablation (PFA) is a non-thermal energy source for pulmonary vein isolation (PVI), offering advantages in safety and procedural efficiency. However, data comparing anterior mitral isthmus line (MIL) ablation using PFA vs. conventional radiofrequency ablation (RFA) are scarce. This study aimed to compare procedural characteristics, safety, and arrhythmia recurrence following PVI with additional anterior MIL ablation using PFA vs. RFA. METHODS AND RESULTS: In this prospective, single-centre analysis from the SWISS-AF-PVI registry, 129 patients (median age 70 years, 40% female) undergoing PVI with anterior MIL ablation were included. Patients received either PFA with a pentaspline catheter (n = 61) or RFA using a 3.5 mm irrigated tip catheter (n = 68). Procedural parameters, complications, and arrhythmia recurrence were assessed over a median follow-up of 327 days. PFA significantly reduced total procedure time (71 vs. 108 min, P < 0.001), LA dwell time (53 vs. 80 min, P < 0.001), and ablation time (27 vs. 50 min, P < 0.001) compared to RFA. MIL ablation with PFA required fewer applications (14; 35 s vs. 473 s RFA, P < 0.001). Arrhythmia-free survival was similar between groups (PFA 48.8% vs. RFA 61.8%, P = 0.34). Among 34 patients undergoing redo procedures, incomplete MIL was found in 53%, with no significant difference between groups. Three major complications occurred. CONCLUSION: Anterior MIL ablation using PFA is feasible, safe, and more time-efficient than RFA, with comparable mid-term arrhythmia outcomes. However, high rates of MIL reconnection and arrhythmia recurrence highlights the need to improve lesion durability.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。